Product Images Pregabalin

The text is a collection of information about various Pregabalin capsules including their quantities, description, expiration dates, and NDC codes. It provides information about the manufacturer and distributor of the capsules, and also warns against dispensing without prescription. However, there is some ambiguous and unclear text, making it difficult to understand the full context.*

This is a list of Pregabalin Capsules of 150mg packaged in quantities of 30 and 60. Each capsule is white opaque and imprinted with SG;354. They are manufactured by ScieGen Pharmaceuticals, Inc. with NDC numbers: 76420-088-30, 76420-098-30, 76420-098-60, 76420-099-30, and 76420-099-60. The mentioned drugs are subject to federal law prohibiting dispensing without prescription, and it should be kept out of reach of children. They should be stored at 20-25C (32.17F) in a USP controlled room.*

The text provides information about the packaging, manufacturing details, drug quantity, lot number, expiry date, source NDC, and drug status of Pregabalin capsules in 200mg strength with NDC numbers 76420-100-30 and 76420-100-60. The capsules are light orange in color and are manufactured by ScieGen Pharmaceuticals, Inc. The text also includes precautions such as avoiding dispensing without prescription, keeping the capsules out of reach of children, and storing them at a controlled room temperature. Overall, the text is a label of Pregabalin capsules used to treat medical conditions such as neuropathic pain and epilepsy.*

This is a packaging label for Pregabalin Capsules, in strengths of 225mg, with NDC codes 76420-101-30 and 76420-101-60, packaged in quantities of 30 and 60. It also includes information about the manufacturer, ScieGen Pharmaceuticals, drug status, instructions for storage and dispensing caution.*

This is a collection of NDCs (National Drug Codes) and their corresponding quantities for Pregabalin Capsule 25mg. The manufacturer is ScieGen Pharmaceuticals, Inc. The capsules are white and opaque with the marking "SG;350". Federal law prohibits dispensing without a prescription, and they should be kept out of reach of children and stored at 20-25 degrees Celsius. The drugs have different statuses, including OV and CV. No further information is available in the text.*

This is a description of Pregabalin Capsules, which are available in different strengths and quantities, including 30 capsules and 60 capsules. The manufacturer is ScieGen Pharmaceuticals, and the source NDC is 50226-357-50. The drug is classified as CV, and the packaging comes with a caution that federal law prohibits dispensing without prescription, and should be kept out of reach of children and stored at 20.25C. The lot number and batch number are also provided for the product.*

This is a collection of labels for Pregabalin Capsules of 50mg from the manufacturer ScieGen Pharmaceuticals, which are packaged in bottles of 30 or 60 capsules. The drug has a Controlled Substance status, and federal law requires a prescription to dispense it. The capsules are white and opaque with the imprint "SG351", and they should be stored at a temperature of 20-25-C controlled room temperature to avoid exposure to children. Batch numbers and expiration dates are also included in the labels.*

The text describes several packages of Pregabalin Capsules of 75mg with different quantities, identifying their NDC and source, batch, and drug status information. It also includes manufacturing information with caution messages for federal laws and storing recommendations.*

This document appears to present information about various Pregabalin capsules produced by ScieGen Pharmaceuticals, Inc. The capsules come in different dosages ranging from 25mg to 300mg and are labeled with different NDGs and batch numbers. The document also provides instructions such as dosage quantity, storage temperature, and other related warnings.*

There is insufficient information to generate a useful description as the text provided is a disorganized set of numbers, symbols, and characters, and does not make coherent sense.*

The text is displaying information in the form of a chart or table, showing different percentages of patient improvement for a medication called Pregabalin 160 mg. The numbers 100, 2, and 10 are not clearly associated with any specific category. The text is not complete and not enough information is given to provide a further description or conclusion.*

The text contains results and dosages related to medical treatment. It is not clear what condition is being treated or what the numbers represent. Therefore, a useful description cannot be generated.*

Not available.*

This appears to be a chart or table displaying different medication dosages and their effectiveness in improving pain for patients. The medications listed are Fregabalin (100mg taken three times a day), Pregataiin (80mg taken three times a day), and Placebo. The chart also shows a percentage of patients who improved with each medication and a percentage of improvement in pain from the baseline. Without additional context or information, it is difficult to determine the exact purpose or significance of this chart.*

This is a table that presents the results of three studies (E1, E3, and S5) comparing the effectiveness of four different doses (placebo, 50mg/day, 150mg/day, 300mg/day, and 600mg/day) of an unknown medication. The text mentions that the results were statistically significant compared to the placebo. The content of the studies or the medication being studied is not specified.*

The text describes a chart that displays the percent improvement in pain from baseline in patients taking pregabalin at different doses and a placebo. The chart shows that the highest improvement percentage was achieved with the highest dose of pregabalin (450mg daily), followed by the lower dose of 300mg daily. The improvement rate with the placebo was much lower.*

This appears to be a table showing the estimated percent of subjects without LTR (likely an abbreviation for some medical condition) for two treatments: Progabain and Placebo. It also includes a time scale measured in days. However, without additional context it is difficult to provide more information or interpretation.*

The data shows the percent of improvement in subjects using Pregabalin versus Placebo from baseline to week 16. The percent of subjects improved is noted as 100 with varying data points ranging from 210 to 280.*

This appears to be a formula for calculating creatinine clearance (CLCT) in patients above the age of 140 years, using their weight in kilograms and serum creatinine levels in milligrams per deciliter (mg/dL). The formula also takes into consideration the patient's gender, as the calculation for female patients involves multiplying the result by 0.85.*